CMV PCR + HBV/HCV/HIV serology + PCP prophylaxis pre-alemtuzumab — alemtuzumab reactivate...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`RF-T-PLL-INFECTION-SCREENING`
Type	Red flag
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-T-PLL`
Sources	`SRC-ESMO-PTCL-2024` `SRC-NCCN-BCELL-2025`

Red Flag Origin

Definition	CMV PCR + HBV/HCV/HIV serology + PCP prophylaxis pre-alemtuzumab — alemtuzumab reactivates CMV in ~30%; PCP prophylaxis mandatory for ≥6 months post-treatment.
Clinical direction	investigate
Category	infection-screening

Trigger Logic

{
  "any_of": [
    {
      "finding": "cmv_pcr_blood_positive",
      "value": true
    },
    {
      "finding": "hbsag",
      "value": "positive"
    }
  ],
  "type": "biomarker"
}

Notes

Alemtuzumab CMV reactivation is the dominant infectious complication; weekly CMV PCR monitoring + pre-emptive ganciclovir threshold is standard of care.

Used By

No reverse references found in the YAML corpus.